Loomis, Sayles & Company
LUMO

Loomis, Sayles & Company’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Loomis, Sayles & Company’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-19
Closed -$3K – 1144
2016
Q1 		$3K Hold
19
– – ﹤0.01% 986
2015
Q4 		$6K Hold
19
– – ﹤0.01% 922
2015
Q3 		$6K Hold
19
– – ﹤0.01% 940
2015
Q2 		$8K Buy
+19
New +$8.07K ﹤0.01% 834

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Loomis, Sayles & Company's LUMO Position: Q2 2016 in Review

Loomis, Sayles & Company sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2016, closing a stake of 19 shares — an estimated $3K sold.

Loomis, Sayles & Company first reported a position in LUMO in Q2 2015 and held it in 4 quarters. The position peaked at $8K in Q2 2015. 112 funds tracked by Wall St. Rank hold LUMO as of Q2 2016.

  • Loomis, Sayles & Company reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
  • Loomis, Sayles & Company sold 19 Lumos Pharma, Inc. Common Stock shares in Q2 2016, an estimated $3K.
  • Loomis, Sayles & Company first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2015 and held it in 4 quarters.
  • Loomis, Sayles & Company's Lumos Pharma, Inc. Common Stock position peaked at $8K in Q2 2015.
  • 112 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2016.

Based on Loomis, Sayles & Company's 13F filing for Q2 2016, filed 12 Aug 2016.